AbbVie reported that its dual-acting bispecific antibody etentamig met the main goal of a Phase 3 trial in multiple myeloma. In the study of 421 patients, etentamig improved survival without progression versus standard regimens for people who had progressed after two or more prior lines. AbbVie said the interim checkpoint led to unblinding, with 393 evaluable patients at an average of 11 months after trial entry. The company also highlighted a safety profile with low rates of serious immune responses tied to other drugs in the class, potentially reducing monitoring intensity for community oncology settings. If confirmed in broader follow-up, the data could move etentamig closer to commercialization and intensify competition among bispecifics that aim to combine efficacy with manageable risk in later-line myeloma.